EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan

Kei Kunimasa iD, Naotoshi Sugimoto, Tomoyuki Yamasaki, Yoji Kukita, Fumie Fujisawa, Tazuko Inoue, Yuko Yamaguchi, Mitsuko Kitasaka, Daisuke Sakai, Keiichiro Honma, Toru Wakamatsu iD, Sachiko Yamamoto und 7 weitere

Cancer Medicine · 2024-09 · 13 (18)

DOI: 10.1002/cam4.70249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.09.2024. Verfasst von Kei Kunimasa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real‐world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and its effectiveness.

Methods

We analyzed data from advanced solid tumor patients who underwent CGP panel between December 2019 and May 2023 at the Osaka International Cancer Institute. Patient demographics, specimen details, and expert panel assessments were collected. Turnaround time (TAT) and genomically matched therapy outcomes were analyzed. Gene alterations and their co‐occurrence patterns were also assessed.

Results

Among 1437 patients, 1096 results were available for analysis. The median TAT was 63 [28–182] days. There were 667 (60.9%) cases wherein recommended clinical trials were presented and there were 12 (1.1%) cases that could be enrolled in the trial and 25 (2.3%) cases that could lead to therapies under insurance reimbursement. The median progression free survival of the trial treatment was 1.58 months (95% CI: 0.66–4.37) in clinical trials and 3.66 months (95% CI: 2.14–7.13) in treatment under insurance. Pathologic germline variants were confirmed in 15 patients (1.3%). Co‐alteration of CDKN2A , CDKN2B , and MTAP was significantly observed in overall population.

Conclusion

The effectiveness of the genomically matched therapy based on the CGP panel was unsatisfactory. Expansion of clinical trials and utilization of remote clinical trials are required to ensure that the results of the CGP panel can be fully returned to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPrecision MedicineHumansMaleFemaleJapanMiddle AgedAgedAdultAged, 80 and overProgression-Free SurvivalYoung AdultGenomicsTreatment OutcomeBiomarkers, Tumor

Stichwörter der Autor:innen

clinical trialcomprehensive genomic profilinggenomically matched therapyreal world datasolid tumor

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Genetic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Endocrinology and Metabolism, Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
  • Laboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Medical Oncology, Shiga General Hospital, Shiga, Japan.

ORCID-Profile: Kei Kunimasa, Toru Wakamatsu

Zitieren

APA

Kunimasa, K., Sugimoto, N., Yamasaki, T., Kukita, Y., Fujisawa, F., Inoue, T., Yamaguchi, Y., Kitasaka, M., Sakai, D., Honma, K., Wakamatsu, T., Yamamoto, S., Hayashi, T., Mabuchi, S., Okuno, J., Kawamura, T., Kai, Y., Urabe, M., & Nishimura, K. (2024). Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan. Cancer Medicine, 13(18). https://doi.org/10.1002/cam4.70249

Vancouver

Kunimasa K, Sugimoto N, Yamasaki T, Kukita Y, Fujisawa F, Inoue T, et al. Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan. Cancer Medicine. 2024;13(18). doi:10.1002/cam4.70249

BibTeX
@article{Kunimasa2024,
  author = {Kunimasa, Kei and Sugimoto, Naotoshi and Yamasaki, Tomoyuki and Kukita, Yoji and Fujisawa, Fumie and Inoue, Tazuko and Yamaguchi, Yuko and Kitasaka, Mitsuko and Sakai, Daisuke and Honma, Keiichiro and Wakamatsu, Toru and Yamamoto, Sachiko and Hayashi, Takuji and Mabuchi, Seiji and Okuno, Jun and Kawamura, Takahisa and Kai, Yugo and Urabe, Makiko and Nishimura, Kazuo},
  title = {Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {18},
  doi = {10.1002/cam4.70249}
}
Kostenlos starten →